Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas

被引:19
作者
Mete, Ozgur [1 ,2 ,3 ]
Pakbaz, Sara [1 ,2 ]
Lerario, Antonio M. [4 ]
Giordano, Thomas J. [4 ,5 ]
Asa, Sylvia L. [6 ,7 ]
机构
[1] Univ Hlth Network, Dept Pathol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Endocrine Oncol Site, Toronto, ON, Canada
[4] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI USA
[5] Univ Michigan, Dept Pathol, Ann Arbor, MI USA
[6] Case Western Reserve Univ, Dept Pathol, Univ Hosp Cleveland, Med Ctr, Cleveland, OH USA
[7] Case Western Reserve Univ, Cleveland, OH USA
关键词
alpha-inhibin; VHL; SDHB; paraganglioma; pheochromocytoma; IMMUNOHISTOCHEMICAL MARKERS; MEDULLARY TUMORS; SDH MUTATIONS; SUBUNIT; PHENOTYPE; PATHWAY; MELAN;
D O I
10.1097/PAS.0000000000001715
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Alpha-inhibin expression has been reported in pheochromocytomas and paragangliomas (PPGLs). We analyzed alpha-inhibin immunohistochemistry in 77 PPGLs (37 pheochromocytomas [PCCs] and 40 paragangliomas) and correlated the results with catecholamine profile, tumor size, Ki-67 labeling index, succinate dehydrogenase B subunit and carbonic anhydrase IX (CAIX) staining, and genetic pathogenesis. PPGLs were classified as pseudohypoxic cluster 1 disease with documented VHL mutation or SDHx mutation or biochemical phenotype, whereas NF1-driven and RET-driven PPGLs and those with a mature secretory (adrenergic or mixed adrenergic and noradrenergic) phenotype were classified as cluster 2 disease. The Cancer Genome Atlas data on INHA expression in PPGLs was examined. Alpha-inhibin was positive in 43 PPGLs (56%). Ki-67 labeling indices were 8.07% and 4.43% in inhibin-positive and inhibin-negative PPGLs, respectively (P<0.05). Alpha-inhibin expression did not correlate with tumor size. Alpha-inhibin was expressed in 92% of SDHx-related and 86% of VHL-related PPGLs. CAIX membranous staining was found in 8 of 51 (16%) tumors, including 1 SDHx-related PCC and all 5 VHL-related PCCs. NF1-driven and RET-driven PPGLs were negative for alpha-inhibin and CAIX. Alpha-inhibin was expressed in 77% of PPGLs with a pseudohypoxia signature, and 20% of PPGLs without a pseudohypoxia signature (P<0.05). PPGLs with a mature secretory phenotype were negative for CAIX. The Cancer Genome Atlas data confirmed higher expression of INHA in cluster 1 than in cluster 2 PPGLs. This study identifies alpha-inhibin as a highly sensitive (90.3%) marker for SDHx/VHL-driven pseudohypoxic PPGLs. Although CAIX has low sensitivity, it is the most specific biomarker of VHL-related pathogenesis. While alpha-inhibin cannot replace succinate dehydrogenase B subunit immunohistochemistry for detection of SDHx-related disease, it adds value in prediction of cluster 1 disease. Importantly, these data emphasize that alpha-inhibin is not a specific marker of adrenal cortical differentiation, as it is also expressed in PCCs.
引用
收藏
页码:1264 / 1273
页数:10
相关论文
共 50 条
[11]   The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas [J].
Andreasson, Adam ;
Kiss, Nimrod B. ;
Caramuta, Stefano ;
Sulaiman, Luqman ;
Svahn, Fredrika ;
Backdahl, Martin ;
Hoog, Anders ;
Juhlin, C. Christofer ;
Larsson, Catharina .
EPIGENETICS, 2013, 8 (12) :1347-1354
[12]   Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors [J].
Sadow, Peter M. ;
Rumilla, Kandelaria M. ;
Erickson, Lori A. ;
Lloyd, Ricardo V. .
ENDOCRINE PATHOLOGY, 2008, 19 (02) :97-103
[13]   Management of Pheochromocytomas and Paragangliomas [J].
Passman, Jesse E. ;
Wachtel, Heather .
SURGICAL CLINICS OF NORTH AMERICA, 2024, 104 (04) :863-881
[14]   Imaging of Pheochromocytomas and Paragangliomas [J].
Timmers, Henri J. L. M. ;
Taieb, David ;
Pacak, Karel ;
Lenders, Jacques W. M. .
ENDOCRINE REVIEWS, 2024, 45 (03) :414-434
[15]   Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas [J].
Job, Sylvie ;
Georges, Adrien ;
Burnichon, Nelly ;
Buffet, Alexandre ;
Amar, Laurence ;
Bertherat, Jerome ;
Bouatia-Naji, Nabila ;
de Reynies, Aurelien ;
Drui, Delphine ;
Lussey-Lepoutre, Charlotte ;
Favier, Judith ;
Gimenez-Roqueplo, Anne-Paule ;
Castro-Vega, Luis Jaime .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03) :898-907
[16]   Genetics of pheochromocytomas and paragangliomas [J].
Opocher, Giuseppe ;
Schiavi, Francesca .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 24 (06) :943-956
[17]   Screening for Pheochromocytomas and Paragangliomas [J].
Graeme Eisenhofer .
Current Hypertension Reports, 2012, 14 :130-137
[18]   Genetics of pheochromocytomas and paragangliomas [J].
Ferreira, Marta Almeida ;
Vilaverde, Joana .
REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2014, 9 (01) :29-35
[19]   Molecular Alterations in Dog Pheochromocytomas and Paragangliomas [J].
Korpershoek, Esther ;
Dieduksman, Daphne A. E. R. ;
Grinwis, Guy C. M. ;
Day, Michael J. ;
Reusch, Claudia E. ;
Hilbe, Monika ;
Fracassi, Federico ;
Krol, Niels M. G. ;
Uitterlinden, Andre G. ;
de Klein, Annelies ;
Eussen, Bert ;
Stoop, Hans ;
de Krijger, Ronald R. ;
Galac, Sara ;
Dinjens, Winand N. M. .
CANCERS, 2019, 11 (05)
[20]   Differential diagnosis of pheochromocytomas and paragangliomas [J].
Anne Marie McNicol .
Endocrine Pathology, 2001, 12 :407-415